Amit Singal, MD, MS

Articles

Role of Systemic Therapy in Early- or Intermediate-Stage HCC

October 7th 2022

Expert perspectives on the selection and use of systemic therapy in patients who progress on or are unsuitable for locoregional therapies.

Role of Locoregional Therapy in Early- or Intermediate-Stage HCC

September 30th 2022

Comprehensive insight on the role of locoregional therapies in early- or intermediate-stage HCC, alone or in combination with systemic agents.

Early- and Intermediate-Stage HCC Treatment Landscape

September 30th 2022

Opening their discussion on the management of hepatocellular carcinoma, expert panelists take a broad look at the treatment landscape.

Dr. Singal on the Results of a Mailed Outreach Strategy for Surveillance Utilization in HCC

September 4th 2021

Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.

Dr. Singal on Downstaging Strategies in HCC

March 26th 2021

Amit Singal, MD, discusses downstaging strategies for patients with hepatocellular carcinoma.

Dr. Singal on the Utility of Frontline Lenvatinib and Sorafenib in Advanced HCC

March 2nd 2021

Amit G. Singal, MD, MS, discusses the utility of frontline lenvatinib and sorafenib in hepatocellular carcinoma.

Dr. Singal on Systemic Therapies in HCC

April 1st 2020

Amit G. Singal, MD, discusses systemic therapies in hepatocellular carcinoma.

Dr. Singal on the Importance of Early Diagnosis in HCC

March 2nd 2020

Amit G. Singal, MD, discusses the importance of early diagnosis for patients with hepatocellular carcinoma.

Dr. Singal on the FDA Approval of Cabozantinib in HCC

January 15th 2019

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the FDA approval of cabozantinib (Cabometyx) for patients with hepatocellular carcinoma (HCC) who previously received sorafenib (Nexavar).

Dr. Singal on the Potential for Immunotherapy in HCC

October 9th 2018

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the potential of immunotherapy in the treatment landscape of hepatocellular carcinoma.

Dr. Singal Discusses Recent Clinical Trials in HCC

September 13th 2018

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses recent clinical trials in hepatocellular carcinoma.

Dr. Singal on Emerging Systemic Therapies in HCC

August 31st 2018

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses emerging systemic therapies in hepatocellular carcinoma.

Dr. Singal Discusses Sequencing Therapy for HCC

August 23rd 2018

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses sequencing therapy for patients with hepatocellular carcinoma.